ME00593B - Derivati 4-fenil-piridina - Google Patents

Derivati 4-fenil-piridina

Info

Publication number
ME00593B
ME00593B MEP-2009-57A MEP5709A ME00593B ME 00593 B ME00593 B ME 00593B ME P5709 A MEP5709 A ME P5709A ME 00593 B ME00593 B ME 00593B
Authority
ME
Montenegro
Prior art keywords
phenyl
pyridine derivatives
pyridine
derivatives
Prior art date
Application number
MEP-2009-57A
Other languages
English (en)
Unknown language (me)
Inventor
Torsten Hoffmann
Patrick Schnider
Michael Boes
Ouirico Branca
Guido Galley
Thierry Godel
Walter Hunkeler
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MEP5709A publication Critical patent/MEP5709A/xx
Publication of ME00593B publication Critical patent/ME00593B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MEP-2009-57A 1999-02-24 2000-02-22 Derivati 4-fenil-piridina ME00593B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99103504 1999-02-24
EP99123689 1999-11-29

Publications (2)

Publication Number Publication Date
MEP5709A MEP5709A (en) 2011-12-20
ME00593B true ME00593B (me) 2015-08-31

Family

ID=26152908

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-57A ME00593B (me) 1999-02-24 2000-02-22 Derivati 4-fenil-piridina

Country Status (55)

Country Link
US (2) US6297375B1 (US07585860-20090908-C00154.png)
EP (2) EP1035115B1 (US07585860-20090908-C00154.png)
JP (1) JP3399900B2 (US07585860-20090908-C00154.png)
KR (1) KR100384904B1 (US07585860-20090908-C00154.png)
CN (1) CN1142144C (US07585860-20090908-C00154.png)
AR (2) AR029614A1 (US07585860-20090908-C00154.png)
AT (2) ATE496032T1 (US07585860-20090908-C00154.png)
AU (1) AU767048B2 (US07585860-20090908-C00154.png)
BE (1) BE2015C057I2 (US07585860-20090908-C00154.png)
BG (1) BG64554B1 (US07585860-20090908-C00154.png)
BR (1) BRPI0000908B8 (US07585860-20090908-C00154.png)
CA (1) CA2299139C (US07585860-20090908-C00154.png)
CY (3) CY1111317T1 (US07585860-20090908-C00154.png)
CZ (1) CZ300596B6 (US07585860-20090908-C00154.png)
DE (3) DE60045564D1 (US07585860-20090908-C00154.png)
DK (2) DK1035115T3 (US07585860-20090908-C00154.png)
EA (1) EA003673B1 (US07585860-20090908-C00154.png)
EG (1) EG23817A (US07585860-20090908-C00154.png)
ES (3) ES2359235T3 (US07585860-20090908-C00154.png)
FR (2) FR2790473B1 (US07585860-20090908-C00154.png)
GB (1) GB2347422A (US07585860-20090908-C00154.png)
GE (1) GEP20022676B (US07585860-20090908-C00154.png)
GT (1) GT200000017A (US07585860-20090908-C00154.png)
HK (1) HK1031223A1 (US07585860-20090908-C00154.png)
HR (2) HRP20000097B1 (US07585860-20090908-C00154.png)
HU (1) HU227629B1 (US07585860-20090908-C00154.png)
IL (1) IL134654A (US07585860-20090908-C00154.png)
IS (1) IS2116B (US07585860-20090908-C00154.png)
IT (1) IT1320763B1 (US07585860-20090908-C00154.png)
JO (1) JO2294B1 (US07585860-20090908-C00154.png)
LT (1) LTC1035115I2 (US07585860-20090908-C00154.png)
LU (1) LU92745I2 (US07585860-20090908-C00154.png)
MA (1) MA26722A1 (US07585860-20090908-C00154.png)
ME (1) ME00593B (US07585860-20090908-C00154.png)
MY (2) MY123648A (US07585860-20090908-C00154.png)
NL (1) NL300758I2 (US07585860-20090908-C00154.png)
NO (1) NO315554B1 (US07585860-20090908-C00154.png)
NZ (1) NZ502948A (US07585860-20090908-C00154.png)
OA (1) OA11680A (US07585860-20090908-C00154.png)
PA (1) PA8491101A1 (US07585860-20090908-C00154.png)
PE (1) PE20001467A1 (US07585860-20090908-C00154.png)
PL (1) PL217311B1 (US07585860-20090908-C00154.png)
PT (2) PT1035115E (US07585860-20090908-C00154.png)
RS (3) RS50194B (US07585860-20090908-C00154.png)
SE (1) SE1035115T5 (US07585860-20090908-C00154.png)
SG (1) SG91856A1 (US07585860-20090908-C00154.png)
SI (1) SI1035115T1 (US07585860-20090908-C00154.png)
SK (2) SK287912B6 (US07585860-20090908-C00154.png)
SV (1) SV2002000024A (US07585860-20090908-C00154.png)
TN (1) TNSN00032A1 (US07585860-20090908-C00154.png)
TR (1) TR200000520A2 (US07585860-20090908-C00154.png)
TW (1) TWI288746B (US07585860-20090908-C00154.png)
UA (1) UA71547C2 (US07585860-20090908-C00154.png)
UY (1) UY32314A (US07585860-20090908-C00154.png)
ZA (1) ZA200000894B (US07585860-20090908-C00154.png)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3979099A (en) * 1998-05-11 1999-11-29 Philadelphia Health & Education Corporation (mct-1), a human oncogene
CZ20013046A3 (cs) 1999-02-24 2002-02-13 F. Hoffmann-La Roche Ag Fenylové a pyridinylové deriváty
US6291465B1 (en) * 1999-03-09 2001-09-18 Hoffmann-La Roche Inc. Biphenyl derivatives
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
JP3938651B2 (ja) * 2000-04-13 2007-06-27 セントラル硝子株式会社 光学活性α−メチル−ビス−３、５−（トリフルオロメチル）ベンジルアミンの製造方法
MXPA03000366A (es) * 2000-07-14 2003-05-27 Hoffmann La Roche N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina.
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
MXPA03005169A (es) * 2000-12-14 2003-09-22 Hoffmann La Roche Matriz lipidica auto-emulsificante.
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
JP4225787B2 (ja) * 2001-03-27 2009-02-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｎ−アリール環状アミン誘導体およびそれを有効成分として含有する医薬
DE60210760T2 (de) * 2001-04-23 2006-11-23 F. Hoffmann-La Roche Ag Verwendung von nk-1-rezeptorantagonisten gegen benigne prostatahyperplasie
CA2449987C (en) * 2001-06-07 2015-11-03 Christine N. Sang Treatment of central neuropathic pain
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
DE60225026T2 (de) * 2001-09-10 2009-02-05 F. Hoffmann-La Roche Ag Ölige thixotrope zusammensetzungen
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
CA2499490A1 (en) 2002-09-20 2004-04-01 Pfizer Products Inc. Amide and sulfonamide ligands for the estrogen receptor
DE60329415D1 (de) * 2002-12-06 2009-11-05 Purdue Research Foundation Pyridine zur behandlung von verletztemsäugetiernervengewebe
US8729107B2 (en) * 2002-12-06 2014-05-20 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
DE602004007486T2 (de) 2003-01-31 2008-04-30 F. Hoffmann-La Roche Ag Neue kristallmodifikation von 2-(3,5-bis-trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-thiomorpholin-4-yl)-4(4-fluor-2-methyl-phenyl)-pyridin-3-yl-n-methyl-isobutyramid
PL1643998T3 (pl) 2003-07-03 2008-01-31 Hoffmann La Roche Podwójni antagoniści NK1/NK3 do leczenia schizofrenii
US7288658B2 (en) * 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
US7335658B2 (en) 2003-07-30 2008-02-26 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
WO2006002860A1 (en) * 2004-07-06 2006-01-12 F. Hoffmann-La Roche Ag Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
KR100881240B1 (ko) * 2004-07-06 2009-02-05 에프. 호프만-라 로슈 아게 Ｎｋ-1 수용체 길항제의 합성에 있어서 중간체로서사용되는 카르복스아미드 피리딘 유도체의 제조 방법
WO2006014168A1 (en) * 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Nicotinamide derivatives and their use as therapeutic agents
WO2006013205A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030556A1 (en) * 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
TW200626139A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CN101083992A (zh) 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
US7569725B2 (en) * 2004-10-21 2009-08-04 Britsol-Myers Squibb Company Anthranilic acid derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase 3
WO2006060174A1 (en) * 2004-11-15 2006-06-08 Honeywell International Inc. Isocyanate-based polymer foams with nano-scale materials
ES2329827T3 (es) * 2005-02-22 2009-12-01 F. Hoffmann-La Roche Ag Antagonistas de nk1.
US7671065B2 (en) * 2005-02-24 2010-03-02 Janssen Pharmaceutica N.V. Pyridine derivatives as potassium ion channel openers
RU2007129642A (ru) 2005-02-25 2009-03-27 Ф.Хоффманн-Ля Рош Аг (Ch) Таблетки с улучшенным распределением лекарственного вещества
PT1863767E (pt) * 2005-03-23 2009-03-27 Hoffmann La Roche Metabolitos para antagonistas de nk-1 para vómitos
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
ATE512145T1 (de) * 2005-08-11 2011-06-15 Vertex Pharma Modulatoren des cystic fibrosis transmembrane conductance regulators
SI1928886T1 (sl) 2005-09-09 2011-08-31 Glaxosmithkline Llc Derivati piridina in njihova uporaba pri zdravljenju psihotiäśnih motenj
MY143784A (en) * 2005-09-23 2011-07-15 Hoffmann La Roche Novel dosage formulation
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7872022B2 (en) * 2006-04-03 2011-01-18 Hoffmann-La Roche Inc. Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
SI2674428T1 (sl) 2006-04-07 2016-07-29 Vertex Pharmaceuticals Incorporated Modulatorji transporterjev atp-vezavne kasete
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
DK2639224T3 (en) * 2007-12-07 2016-10-17 Vertex Pharma A process for the preparation of cycloalkylcarboxiamido-pyridinbenzoesyrer
NZ702159A (en) 2007-12-07 2016-03-31 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20100317663A1 (en) * 2008-02-19 2010-12-16 Jerry Leroy Adams Anilinopyridines as inhibitors of fak
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
ES2440938T3 (es) * 2009-08-27 2014-01-31 Nerre Therapeutics Limited Formas anhidrato de un derivado de piridina
CN106512010A (zh) 2009-11-18 2017-03-22 赫尔辛医疗股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
TW201143768A (en) * 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
EP3150198B1 (en) 2010-04-07 2021-09-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyriodin-2-yl)benzoic acid and administration thereof
SI2555754T1 (sl) 2010-04-07 2016-07-29 Vertex Pharmaceuticals Incorporated Trdne farmacevtske oblike 3-(6-(1-(2,2-difluoro-benzo(d)(1,3)dioksol-5- il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline
EP3045452A1 (en) 2010-04-22 2016-07-20 Vertex Pharmaceuticals Inc. Process of producing cycloalkylcarboxamido-indole compounds
EP2560488B1 (en) * 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
EP2736329A4 (en) * 2011-07-29 2015-03-25 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
US20140256740A1 (en) * 2011-07-29 2014-09-11 Tempero Pharmaceuticals, Inc. Compounds and methods
PL2744497T3 (pl) 2011-10-18 2016-10-31 Terapeutyczne połączenia netupitantu i palonosetronu
RU2640420C2 (ru) 2011-11-08 2018-01-09 Вертекс Фармасьютикалз Инкорпорейтед Модуляторы транспортеров атф-связывающей кассеты
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9012496B2 (en) 2012-07-16 2015-04-21 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof
AU2014347644B2 (en) * 2013-11-08 2018-06-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
KR102280372B1 (ko) 2013-11-12 2021-07-22 버텍스 파마슈티칼스 인코포레이티드 Cftr 매개된 질환 치료용 약제학적 조성물의 제조 방법
HUE062736T2 (hu) 2014-04-15 2023-12-28 Vertex Pharma Gyógyszerészeti készítmények cisztás fibrózis transzmembrán konduktancia regulátor által mediált betegségek kezelésére
US20150315149A1 (en) * 2014-05-05 2015-11-05 Apicore Us Llc Methods of making netupitant and intermediates thereof
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
TW201613888A (en) 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
HUE055423T2 (hu) 2014-11-18 2021-11-29 Vertex Pharma Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére
WO2016141341A1 (en) 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CN105061303A (zh) * 2015-08-03 2015-11-18 成都欣捷高新技术开发有限公司 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
EP3347011A4 (en) 2015-09-11 2019-06-19 Chase Pharmaceuticals Corporation MUSCARIN COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGEN DISORDERS OF THE CENTRAL NERVOUS SYSTEM
WO2017099049A1 (ja) * 2015-12-07 2017-06-15 キッセイ薬品工業株式会社 Ｎｋ１受容体拮抗剤
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TW202246215A (zh) * 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
CN106892864A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种奈妥皮坦游离碱的晶型a及其制备方法
EA201891472A1 (ru) 2015-12-22 2018-12-28 Такеда Фармасьютикал Компани Лимитед Тройные модуляторы эндосомальных рецепторов, сопряженных с g-белком
MX2019012088A (es) 2017-04-10 2020-02-07 Chase Therapeutics Corp Combinacion de antagonista nk1 y metodo para tratar sinucleinopatias.
EP3645120A4 (en) 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION
CN109384712B (zh) * 2017-08-14 2021-05-07 北京宽厚医药科技有限公司 靶向nk1受体拮抗剂及其在化疗所致恶心、呕吐治疗中的应用
EP3672964A4 (en) 2017-08-21 2021-05-26 Leiutis Pharmaceuticals Pvt. Ltd. NEW TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY
AU2019348001B2 (en) * 2018-09-28 2023-09-21 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
JP2022514782A (ja) * 2018-12-24 2022-02-15 ユーストラリス ファーマシューティカルズ リミテッド （トレーディング アズ プレススラ ニューロ） 化合物の製造、その新しい塩形態および治療的使用
CN112174881B (zh) * 2019-07-04 2022-06-21 上海森辉医药有限公司 一种奈妥匹坦的衍生物及其制备方法
KR20220165251A (ko) 2020-04-03 2022-12-14 네르 쎄라퓨틱스 리미티드 패혈증, 패혈성 쇼크, 급성 호흡 곤란 증후군 (ards) 또는 다발성 기관 기능장애 증후군 (mods)으로부터 선택된 질환을 치료하기 위한 nk-1 수용체 길항제
US11872222B2 (en) 2020-06-02 2024-01-16 Nerre Therapeutics Limited Uses
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
WO2024126398A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Fixed dose combination comprising netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1557420A (en) 1977-03-10 1979-12-12 Soc D Etudes Prod Chimique Preparation of isobutyramide derivatives
KR810001320B1 (ko) 1977-03-17 1981-10-14 삐에르 위브 신규한 이소부티라미드류의 제조방법
KR810001697B1 (ko) 1978-02-06 1981-10-27 삐에르 위브 이소부티라미드 유도체의 신규한 제조방법
EP0089153B1 (en) 1982-03-17 1986-09-24 Smith Kline & French Laboratories Limited Pyridine derivatives
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
GB8607312D0 (en) 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
GB8607313D0 (en) 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
CA1339423C (en) 1988-09-14 1997-09-02 Yuji Ono Pyridine compounds and pharmaceutical use thereof
US4994456A (en) 1989-03-01 1991-02-19 Nisshin Flour Milling Co., Ltd. Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
US4973597A (en) 1989-06-30 1990-11-27 Eli Lilly And Company Anticonvulsant agents
HU207047B (en) 1989-11-07 1993-03-01 Richter Gedeon Vegyeszet Process for producing new pyridine derivatives and pharmaceutical copositions comprising same
US5364943A (en) 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
GB9021056D0 (en) 1990-09-27 1990-11-07 Pfizer Ltd Antiarrhythmic agents
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
AU4718093A (en) 1992-07-31 1994-03-03 Merck Sharp & Dohme Limited Substituted amines as tachykinin receptor antagonists
US5387595A (en) 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
GB9305672D0 (en) 1993-03-19 1993-05-05 Wyeth John & Brother Ltd Amide derivatives
NZ264063A (en) 1993-08-13 1995-11-27 Nihon Nohyaku Co Ltd N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
EP0737192B1 (en) * 1993-12-29 2001-10-31 Merck Sharp & Dohme Ltd. Substituted morpholine derivatives and their use as therapeutic agents
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
WO1995033744A1 (en) 1994-06-06 1995-12-14 Warner-Lambert Company Tachykinin (nk1) receptor antagonists
US6294537B1 (en) 1995-03-17 2001-09-25 Sanofi-Synthelabo Compounds which are specific antagonists of the human NK3 receptor and their use as medicinal products and diagnostic tools
ES2194937T3 (es) * 1995-03-24 2003-12-01 Takeda Chemical Industries Ltd Compuestos ciclicos, su produccion y uso como antagonistas de los receptores de taquiquinina.
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
EP1471055A1 (en) 1996-03-29 2004-10-27 Pfizer Inc. 6-phenylpyridyl-2-amine derivatives
AU4885097A (en) 1996-11-08 1998-06-03 Sankyo Company Limited Arylureas or arylmethylcarbamoyl derivatives
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
CZ20013046A3 (cs) * 1999-02-24 2002-02-13 F. Hoffmann-La Roche Ag Fenylové a pyridinylové deriváty
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida

Also Published As

Publication number Publication date
EP1394150A1 (en) 2004-03-03
UA71547C2 (uk) 2004-12-15
IS5381A (is) 2000-08-25
ITMI20000328A1 (it) 2001-08-23
JP2000247957A (ja) 2000-09-12
AR062949A2 (es) 2008-12-17
ATE496032T1 (de) 2011-02-15
DE60045564D1 (de) 2011-03-03
MEP5709A (en) 2011-12-20
CZ2000609A3 (cs) 2001-01-17
IT1320763B1 (it) 2003-12-10
TWI288746B (en) 2007-10-21
SK287912B6 (sk) 2012-03-02
CY2015042I1 (el) 2016-06-22
ES2171109B2 (es) 2003-09-16
DE60014216D1 (de) 2004-11-04
LU92745I2 (fr) 2015-08-17
BE2015C057I2 (US07585860-20090908-C00154.png) 2019-03-06
MY123648A (en) 2006-05-31
DK1035115T3 (da) 2005-01-24
BRPI0000908B8 (pt) 2021-05-25
HU227629B1 (en) 2011-10-28
TR200000520A3 (tr) 2001-06-21
CY1111317T1 (el) 2015-08-05
GEP20022676B (en) 2002-04-25
NO315554B1 (no) 2003-09-22
MY147451A (en) 2012-12-14
OA11680A (fr) 2005-01-12
DE60014216T2 (de) 2006-03-02
ITMI20000328A0 (it) 2000-02-23
SE1035115T5 (sv) 2015-08-04
CY2015041I1 (el) 2016-06-22
EA200000155A2 (ru) 2000-08-28
IS2116B (is) 2006-06-15
EP1394150B1 (en) 2011-01-19
US6297375B1 (en) 2001-10-02
MA26722A1 (fr) 2004-12-20
PE20001467A1 (es) 2000-12-20
NO20000885D0 (no) 2000-02-23
JP3399900B2 (ja) 2003-04-21
DE10008042A1 (de) 2000-08-31
DK1394150T3 (da) 2011-03-21
BR0000908B1 (pt) 2013-09-24
SV2002000024A (es) 2002-01-23
PT1035115E (pt) 2005-01-31
IL134654A (en) 2011-03-31
HRP20080306A2 (en) 2008-11-30
NO20000885L (no) 2000-08-25
PL217311B1 (pl) 2014-07-31
BG104187A (en) 2000-11-30
HRP20000097A2 (en) 2001-10-31
FR15C0049I2 (fr) 2016-02-12
CA2299139C (en) 2011-03-29
ZA200000894B (en) 2000-08-24
GT200000017A (es) 2001-08-15
HRP20080306B1 (hr) 2015-01-30
SE1035115T3 (sv) 2005-01-18
EA003673B1 (ru) 2003-08-28
AU767048B2 (en) 2003-10-30
EP1035115A1 (en) 2000-09-13
CN1142144C (zh) 2004-03-17
FR2790473A1 (fr) 2000-09-08
CZ300596B6 (cs) 2009-06-24
US6479483B2 (en) 2002-11-12
AU1946800A (en) 2000-08-31
AR029614A1 (es) 2003-07-10
HUP0000748A3 (en) 2003-12-29
FR2790473B1 (fr) 2004-04-02
GB2347422A (en) 2000-09-06
PL338598A1 (en) 2000-08-28
LTC1035115I2 (lt) 2017-04-10
ES2171109A1 (es) 2002-08-16
EP1035115B1 (en) 2004-09-29
EA200000155A3 (ru) 2000-12-25
HU0000748D0 (en) 2000-04-28
PT1394150E (pt) 2011-02-17
TR200000520A2 (tr) 2001-06-21
KR100384904B1 (ko) 2003-05-22
EG23817A (en) 2007-09-19
ES2226622T3 (es) 2005-04-01
PA8491101A1 (es) 2001-04-30
SI1035115T1 (en) 2005-02-28
CA2299139A1 (en) 2000-08-24
HK1031223A1 (en) 2001-06-08
HUP0000748A2 (en) 2001-03-28
HRP20000097B1 (en) 2008-12-31
IL134654A0 (en) 2001-04-30
KR20000062599A (ko) 2000-10-25
RS20080562A (en) 2009-09-08
YU9500A (sh) 2002-11-15
BG64554B1 (bg) 2005-07-29
CN1270959A (zh) 2000-10-25
TNSN00032A1 (fr) 2005-11-10
ATE277905T1 (de) 2004-10-15
SG91856A1 (en) 2002-10-15
BR0000908A (pt) 2000-09-12
FR15C0049I1 (fr) 2015-08-28
NL300758I1 (US07585860-20090908-C00154.png) 2015-12-22
US20020091265A1 (en) 2002-07-11
ES2359235T3 (es) 2011-05-19
SK287911B6 (sk) 2012-03-02
GB0003908D0 (en) 2000-04-05
LTPA2015036I1 (lt) 2015-11-25
RS53869B1 (en) 2015-08-31
CY2015041I2 (el) 2016-06-22
NL300758I2 (US07585860-20090908-C00154.png) 2015-12-22
NZ502948A (en) 2001-09-28
SK2352000A3 (en) 2000-09-12
UY32314A (es) 2010-02-26
JO2294B1 (en) 2005-09-12
RS50194B (sr) 2009-05-06

Similar Documents

Publication Publication Date Title
EG23817A (en) 4-Phenyl-pyridine derivatives
HUP0201535A2 (en) 5-cyano-2-aminopyrimidine derivatives
IL148167A0 (en) Amino-triazolopyridine derivatives
GC0000183A (en) 3-Phenyl-pyridine derivatives
IL145739A0 (en) 13-methyl-erythromycin derivatives
GC0000338A (en) 5-Phenyl-pyrimidine derivatives
IL148837A0 (en) Isoxazolecarboxamide derivatives
GC0000191A (en) 4-Phenyl-pyrimidine derivatives
GB9925880D0 (en) B-Carboline derivatives
GC0000256A (en) Ethanesulfonyl-piperidine derivatives
IL147636A0 (en) 3-amino-2-benzyl-1-phenyl-propane derivatives
IL150132A0 (en) Cyclopenteneone derivatives
IL145949A0 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
PL351407A1 (en) Thio-oxindole derivatives
IL146282A0 (en) Thio-oxindole derivatives
GB9907134D0 (en) Antimor napthylcombretastatin derivatives
SI1178984T1 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
SI1226131T1 (en) Isoxazolecarboxamide derivatives
HK1043987A1 (zh) 硫-羥吲衍生物
SI1200445T1 (en) Thienopyranecarboxamide derivatives